263 related articles for article (PubMed ID: 26607297)
1. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
Yabe D; Seino Y
Expert Opin Drug Saf; 2016; 15(2):249-64. PubMed ID: 26607297
[TBL] [Abstract][Full Text] [Related]
2. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
[TBL] [Abstract][Full Text] [Related]
4. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
Deacon CF
Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
[TBL] [Abstract][Full Text] [Related]
5. Alogliptin (nesina) for type 2 diabetes.
Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
[No Abstract] [Full Text] [Related]
6. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
[TBL] [Abstract][Full Text] [Related]
7. Alogliptin benzoate for the treatment of type 2 diabetes.
Seino Y; Yabe D
Expert Opin Pharmacother; 2014 Apr; 15(6):851-63. PubMed ID: 24646052
[TBL] [Abstract][Full Text] [Related]
8. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
9. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
[TBL] [Abstract][Full Text] [Related]
10. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
Ndefo UA; Okoli O; Erowele G
Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
[TBL] [Abstract][Full Text] [Related]
11. An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes.
Hu J; Yang C; Wang H; Li J; Tan X; Wang J; Zhang B; Zhao Y
Expert Opin Pharmacother; 2019 Oct; 20(14):1679-1687. PubMed ID: 31335214
[No Abstract] [Full Text] [Related]
12. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
[TBL] [Abstract][Full Text] [Related]
13. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
White WB; Cannon CP; Heller SR; Nissen SE; Bergenstal RM; Bakris GL; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Cushman WC; Zannad F;
N Engl J Med; 2013 Oct; 369(14):1327-35. PubMed ID: 23992602
[TBL] [Abstract][Full Text] [Related]
14. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
Jarvis CI; Cabrera A; Charron D
Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
DeFronzo RA; Fleck PR; Wilson CA; Mekki Q;
Diabetes Care; 2008 Dec; 31(12):2315-7. PubMed ID: 18809631
[TBL] [Abstract][Full Text] [Related]
18. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Fujii Y; Abe M; Higuchi T; Mizuno M; Suzuki H; Matsumoto S; Ito M; Maruyama N; Okada K; Soma M
Expert Opin Pharmacother; 2013 Feb; 14(3):259-67. PubMed ID: 23289982
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
20. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Rosenstock J; Wilson C; Fleck P
Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
